A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia

Journal of Medical Economics

Volumn 16, Issue 6, 2013, Pages 720-735

  Dulisse, Brian ^a   Li, Xiaoyan ^b   Gayle, Julie A ^a   Barron, Richard L ^b   Ernst, Frank R ^a   Rothman, Kenneth J ^c   Legg, Jason C ^b   Kaye, James A ^c  

^a Premier Healthcare Alliance   (United States)

^b AMGEN INC   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cancer; Cost; Febrile neutropenia; Hospitalization; Inpatient; Length of stay; Mortality

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANDIDIASIS; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; FATALITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEALTH CARE FACILITY; HODGKIN DISEASE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INFECTION; INJECTION SITE INFECTION; LENGTH OF STAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; PNEUMONIA; PRIMARY TUMOR; RETROSPECTIVE STUDY; SEPTICEMIA; URINARY TRACT INFECTION;

AGED; COST OF ILLNESS; DATABASES, FACTUAL; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84878912559     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.782034     Document Type: Article

References (32)

1. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64
2. Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-60
3. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
4. Kozma CM, Dickson M, Chia V, et al. Trends in neutropenia-related inpatient events. J Oncol Pract 2012;8:149-55
5. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103:1916-24
6. Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011;2:859-66
7. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21 (5 Suppl):v252-6
8. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-93
9. Klastersky J, Awada A, Paesmans M, et al. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011;78:185-94
10. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51
11. American Hospital Association. 2007 AHA Hospital Statistics. Chicago, IL: Health Forum, LLC. 2006.
12. Ernst FR, Davis TE, Ryan AC, et al. Linkage of a multi-hospital database to health plan claims data for continuum of care outcomes research [Abstract and Poster]. Orlando, FL: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2009
13. Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23
14. NCCN Clinical Practice Guidelines in Oncology, 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/infections.pdf [Last accessed 20 December 2012]
15. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
16. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
17. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8
18. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-34
19. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22
20. Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011;29:3977-83
21. Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
22. Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8-18
23. Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in inpatient and outpatient settings [Abstract and Poster]. Atlanta, GA: American Society of Hematology Annual Meeting, 2012
24. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-83
25. Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-94
26. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011;29:3984-9
27. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93
28. Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-52
29. NCCN Clinical Practice Guidelines in Oncology, 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf [Last accessed 20 December 2012]
30. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
31. Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006;17:647-54
32. Weycker D, Sofrygin O, Seefeld K, et al. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 2013;13:60